Triclosan elevates estradiol levels in serum and tissues of cycling and peri-implantation female mice

Reproductive Toxicology

Volumn 65, Issue , 2016, Pages 394-401

  Pollock, Tyler ^a   Greville, Lucas J ^a   Tang, Brandon ^a   deCatanzaro, Denys ^a  

^a MCMASTER UNIVERSITY   (Canada)

Author keywords

Estradiol; Estrogens; Sulfotransferase; Triclosan; Uterus

Indexed keywords

ESTRADIOL; SULFOTRANSFERASE; TRICLOSAN; ESTROGEN;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; ESTRADIOL BLOOD LEVEL; ESTROGEN METABOLISM; ESTROGEN URINE LEVEL; FEMALE; MENSTRUAL CYCLE; MOUSE; NONHUMAN; SULFONATION; UTERUS; ANIMAL; BLOOD; NIDATION; TISSUE DISTRIBUTION; URINE;

ANIMALS; EMBRYO IMPLANTATION; ESTRADIOL; ESTROGENS; FEMALE; MICE; TISSUE DISTRIBUTION; TRICLOSAN;

EID: 84987897220     PISSN: 08906238     EISSN: 18731708     Source Type: Journal    
DOI: 10.1016/j.reprotox.2016.09.004     Document Type: Article

References (58)

1. [1] Heath, R.J., Rubin, J.R., Holland, D.R., Zhang, E., Snow, M.E., Rock, C.O., Mechanism of triclosan inhibition of bacterial fatty acid synthesis. J. Biol. Chem. 274 (1999), 11110–11114, 10.1074/jbc.274.16.11110.
2. [2] Fang, J.-L., Stingley, R.L., Beland, F.A., Harrouk, W., Lumpkins, D.L., Howard, P., Occurrence, efficacy, metabolism, and toxicity of triclosan. J. Environ. Sci. Health C 28 (2010), 147–171, 10.1080/10590501.2010.504978.
3. [3] Rodricks, J.V., Swenberg, J.A., Borzelleca, J.F., Maronpot, R.R., Shipp, A.M., Triclosan: a critical review of the experimental data and development of margins of safety for consumer products. Crit. Rev. Toxicol. 40 (2010), 422–484, 10.3109/10408441003667514.
4. [4] Perencevich, E.N., Wong, M.T., Harris, A.D., National and regional assessment of the antibacterial soap market: a step toward determining the impact of prevalent antibacterial soaps. Am. J. Infect. Control 29 (2001), 281–283.
5. [5] Moss, T., Howes, D., Williams, F.M., Percutaneous penetration and dermal metabolism of triclosan (2 4,4′-trichloro-2′-hydroxydiphenyl ether). Food Chem. Toxicol. 38 (2000), 361–370, 10.1016/S0278-6915(99)00164-7.
6. [6] Queckenberg, C., Meins, J., Wachall, B., Doroshyenko, O., Tomalik-Scharte, D., Bastian, B., Abdel-Tawab, M., Fuhr, U., Absorption, pharmacokinetics, and safety of triclosan after dermal administration. Antimicrob. Agents Chemother. 54 (2010), 570–572, 10.1128/AAC.00615-09.
7. [7] Sandborgh-Englund, G., Adolfsson-Erici, M., Odham, G., Ekstrand, J., Pharmacokinetics of triclosan following oral ingestion in humans. J. Toxicol. Environ. Health A 69 (2006), 1861–1873, 10.1080/15287390600631706.
8. [8] Calafat, A.M., Ye, X., Wong, L.-Y., Reidy, J.A., Needham, L.L., Urinary concentrations of triclosan in the U.S. population: 2003–2004. Environ. Health Perspect. 116 (2008), 303–307, 10.1289/ehp.10768.
9. [9] Han, C., Lim, Y.-H., Hong, Y.-C., Ten-year trends in urinary concentrations of triclosan and benzophenone-3 in the general U.S. population from 2003 to 2012. Environ. Pollut. 208 (2016), 803–810, 10.1016/j.envpol.2015.11.002.
10. [10] Allmyr, M., Harden, F., Toms, L.-M.L., Mueller, J.F., McLachlan, M.S., Adolfsson-Erici, M., Sandborgh-Englund, G., The influence of age and gender on triclosan concentrations in Australian human blood serum. Sci. Total Environ. 393 (2008), 162–167, 10.1016/j.scitotenv.2007.12.006.
11. [11] Geens, T., Neels, H., Covaci, A., Sensitive and selective method for the determination of bisphenol-A and triclosan in serum and urine as pentafluorobenzoate-derivatives using GC–ECNI/MS. J. Chromatogr. B 877 (2009), 4042–4046, 10.1016/j.jchromb.2009.10.017.
12. [12] Allmyr, M., Adolfsson-Erici, M., McLachlan, M.S., Sandborgh-Englund, G., Triclosan in plasma and milk from Swedish nursing mothers and their exposure via personal care products. Sci. Total Environ. 372 (2006), 87–93, 10.1016/j.scitotenv.2006.08.007.
13. [13] Toms, L.-M.L., Allmyr, M., Mueller, J.F., Adolfsson-Erici, M., McLachlan, M., Murby, J., Harden, F.A., Triclosan in individual human milk samples from Australia. Chemosphere 85 (2011), 1682–1686, 10.1016/j.chemosphere.2011.08.009.
14. [14] Geens, T., Neels, H., Covaci, A., Distribution of bisphenol-A, triclosan and n-nonylphenol in human adipose tissue, liver and brain. Chemosphere 87 (2012), 796–802, 10.1016/j.chemosphere.2012.01.002.
15. [15] Kim, J.-Y., Yi, B.-R., Go, R.-E., Hwang, K.-A., Nam, K.-H., Choi, K.-C., Methoxychlor and triclosan stimulates ovarian cancer growth by regulating cell cycle- and apoptosis-related genes via an estrogen receptor-dependent pathway. Environ. Toxicol. Pharmacol. 37 (2014), 1264–1274, 10.1016/j.etap.2014.04.013.
16. [16] Lee, H.-R., Hwang, K.-A., Nam, K.-H., Kim, H.-C., Choi, K.-C., Progression of breast cancer cells was enhanced by endocrine-disrupting chemicals, triclosan and octylphenol, via an estrogen receptor-dependent signaling pathway in cellular and mouse xenograft models. Chem. Res. Toxicol. 27 (2014), 834–842, 10.1021/tx5000156.
17. [17] Stoker, T.E., Gibson, E.K., Zorrilla, L.M., Triclosan exposure modulates estrogen-dependent responses in the female Wistar rat. Toxicol. Sci. 117 (2010), 45–53, 10.1093/toxsci/kfq180.
18. [18] Louis, G.W., Hallinger, D.R., Stoker, T.E., The effect of triclosan on the uterotrophic response to extended doses of ethinyl estradiol in the weanling rat. Reprod. Toxicol. 36 (2013), 71–77, 10.1016/j.reprotox.2012.12.001.
19. [19] Gee, R.H., Charles, A., Taylor, N., Darbre, P.D., Oestrogenic and androgenic activity of triclosan in breast cancer cells. J. Appl. Toxicol. 28 (2008), 78–91, 10.1002/jat.1316.
20. [20] Henry, N.D., Fair, P.A., Comparison of in vitro cytotoxicity, estrogenicity and anti-estrogenicity of triclosan, perfluorooctane sulfonate and perfluorooctanoic acid: in vitro cytotoxicity and estrogenicity of emerging contaminants. J. Appl. Toxicol. 33 (2013), 265–272, 10.1002/jat.1736.
21. [21] James, M.O., Li, W., Summerlot, D.P., Rowland-Faux, L., Wood, C.E., Triclosan is a potent inhibitor of estradiol and estrone sulfonation in sheep placenta. Environ. Int. 36 (2010), 942–949, 10.1016/j.envint.2009.02.004.
22. [22] James, M., Ambadapadi, S., Falany, C., Triclosan inhibits the activity of expressed human sulfotransferases (SULTs) towards their diagnostic substrates. FASEB J., 29, 2015, 622 (Abstract).
23. [23] Wang, L., Falany, C.N., James, M.O., Triclosan as a substrate and inhibitor of 3′-phosphoadenosine 5′-phosphosulfate-sulfotransferase and UDP-glucuronosyl transferase in human liver fractions. Drug Metab. Dispos. 32 (2004), 1162–1169, 10.1124/dmd.104.000273.
24. 14C-bisphenol A in tissues of female and male mice. Toxicol. Appl. Pharmacol. 278 (2014), 116–123, 10.1016/j.taap.2014.04.017.
25. [25] Berger, R.G., Foster, W.G., deCatanzaro, D., Bisphenol-A exposure during the period of blastocyst implantation alters uterine morphology and perturbs measures of estrogen and progesterone receptor expression in mice. Reprod. Toxicol. 30 (2010), 393–400, 10.1016/j.reprotox.2010.06.006.
26. [26] Berger, R.G., Shaw, J., deCatanzaro, D., Impact of acute bisphenol-A exposure upon intrauterine implantation of fertilized ova and urinary levels of progesterone and 17β-estradiol. Reprod. Toxicol. 26 (2008), 94–99, 10.1016/j.reprotox.2008.06.007.
27. [27] Berger, R.G., Hancock, T., deCatanzaro, D., Influence of oral and subcutaneous bisphenol-A on intrauterine implantation of fertilized ova in inseminated female mice. Reprod. Toxicol. 23 (2007), 138–144, 10.1016/j.reprotox.2006.09.005.
28. [28] Borman, E.D., Foster, W.G., Greenacre, M.K.E., Muir, C.C., deCatanzaro, D., Stress lowers the threshold dose at which bisphenol A disrupts blastocyst implantation, in conjunction with decreased uterine closure and e-cadherin. Chem. Biol. Interact. 237 (2015), 87–95, 10.1016/j.cbi.2015.05.012.
29. [29] Crawford, B.R., deCatanzaro, D., Disruption of blastocyst implantation by triclosan in mice: impacts of repeated and acute doses and combination with bisphenol-A. Reprod. Toxicol. 34 (2012), 607–613, 10.1016/j.reprotox.2012.09.008.
30. [30] deCatanzaro, D., Sex steroids as pheromones in mammals: the exceptional role of estradiol. Horm. Behav. 68 (2015), 103–116, 10.1016/j.yhbeh.2014.08.003.
31. [31] Beral, V., Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet 362 (2003), 419–427, 10.1016/S0140-6736(03)14065-2.
32. [32] Beral, V., Endometrial cancer and hormone-replacement therapy in the Million Women Study. Lancet 365 (2005), 1543–1551, 10.1016/S0140-6736(05)66455-0.
33. [33] Beral, V., Ovarian cancer and hormone replacement therapy in the Million Women Study. Lancet 369 (2007), 1703–1710, 10.1016/S0140-6736(07)60534-0.
34. [34] Ma, W., Song, H., Das, S.K., Paria, B.C., Dey, S.K., Estrogen is a critical determinant that specifies the duration of the window of uterine receptivity for implantation. Proc. Natl. Acad. Sci. 100 (2003), 2963–2968.
35. 3H]progesterone from conspecifics to cohabiting female mice. J. Endocrinol. 217 (2013), 1–10, 10.1530/JOE-12-0279.
36. [36] Thorpe, J.B., deCatanzaro, D., Oestradiol treatment restores the capacity of castrated males to induce both the Vandenbergh and the Bruce effects in mice (Mus musculus). Reproduction 143 (2012), 123–132, 10.1530/REP-11-0251.
37. [37] Pollock, T., deCatanzaro, D., Presence and bioavailability of bisphenol A in the uterus of rats and mice following single and repeated dietary administration at low doses. Reprod. Toxicol. 49 (2014), 145–154, 10.1016/j.reprotox.2014.08.005.
38. [38] Guzzo, A.C., Jheon, J., Imtiaz, F., deCatanzaro, D., Oestradiol transmission from males to females in the context of the Bruce and Vandenbergh effects in mice (Mus musculus). Reproduction 143 (2012), 539–548, 10.1530/REP-11-0375.
39. [39] Muir, C., Spironello-Vella, E., Pisani, N., deCatanzaro, D., Enzyme immunoassay of 17β-estradiol, estrone conjugates, and testosterone in urinary and fecal samples from male and female mice. Horm. Metab. Res. 33 (2001), 653–658, 10.1055/s-2001-18692.
40. [40] R: A Language and Environment for Statistical Computing, R Foundation for Statistical Computing. 2015, R. Core Team, Vienna, Austria http://www.R-project.org/.
41. [41] Holm, S., A simple sequentially rejective multiple test procedure. Scand. J. Stat. 6 (1979), 65–70.
42. [42] Haisenleder, D.J., Schoenfelder, A.H., Marcinko, E.S., Geddis, L.M., Marshall, J.C., Estimation of estradiol in mouse serum samples: evaluation of commercial estradiol immunoassays. Endocrinology 152 (2011), 4443–4447, 10.1210/en.2011-1501.
43. [43] deCatanzaro, D., Muir, C., Beaton, E., Jetha, M., Nadella, K., Enzymeimmunoassay of oestradiol, testosterone and progesterone in urine samples from female mice before and after insemination. Reproduction 126 (2003), 407–414.
44. [44] deCatanzaro, D., Muir, C., Beaton, E.A., Jetha, M., Non-invasive repeated measurement of urinary progesterone 17β-estradiol, and testosterone in developing, cycling, pregnant, and postpartum female mice. Steroids 69 (2004), 687–696, 10.1016/j.steroids.2004.07.002.
45. [45] Thorpe, J.B., Burgess, P.S., Sadkowski, M., deCatanzaro, D., Estrogen–progesterone balance in the context of blastocyst implantation failure induced by predator stress. Psychoneuroendocrinology 38 (2013), 3048–3056, 10.1016/j.psyneuen.2013.09.001.
46. [46] Thorpe, J., Gould, K., Borman, E., deCatanzaro, D., Circulating and urinary adrenal corticosterone, progesterone, and estradiol in response to acute stress in female mice (Mus musculus). Horm. Metab. Res. 46 (2014), 211–218, 10.1055/s-0033-1363958.
47. [47] van den Heuvel, M.W., van Bragt, A.J.M., Alnabawy, A.K.M., Kaptein, M.C.J., Comparison of ethinylestradiol pharmacokinetics in three hormonal contraceptive formulations: the vaginal ring, the transdermal patch and an oral contraceptive. Contraception 72 (2005), 168–174, 10.1016/j.contraception.2005.03.005.
48. [48] Couse, J.F., Lindzey, J., Grandien, K., Gustafsson, J., Korach, K.S., Tissue distribution and quantitative analysis of estrogen receptor-α (ERα) and estrogen receptor-β (ERβ) messenger ribonucleic acid in the wild-type and ERα-knockout mouse. Endocrinology 138 (1997), 4613–4621.
49. [49] Kuiper, G.G., Carlsson, B.O., Grandien, K.A.J., Enmark, E., Häggblad, J., Nilsson, S., Gustafsson, J.-A., Comparison of the ligand binding specificity and transcript tissue distribution of estrogen receptors α and β. Endocrinology 138 (1997), 863–870.
50. [50] Mosher, W.D., Jones, J., Use of Contraception in the United States: 1982–2008, U.S. Dept. of Health and Human Services, Centers for Disease Control and Prevention. 2010, National Center for Health Statistics, Hyattsville, Md.
51. [51] Yager, J.D., Davidson, N.E., Estrogen carcinogenesis in breast cancer. N. Engl. J. Med. 354 (2006), 270–282.
52. [52] Jung, E.-M., An, B.-S., Choi, K.-C., Jeung, E.-B., Potential estrogenic activity of triclosan in the uterus of immature rats and rat pituitary GH3 cells. Toxicol. Lett. 208 (2012), 142–148, 10.1016/j.toxlet.2011.10.017.
53. [53] Nazaroff, W., Weschler, C.J., Little, J.C., Hubal, E.A.C., Intake to production ratio: a measure of exposure intimacy for manufactured chemicals. Environ. Health Perspect. 120 (2012), 1678–1683.
54. [54] Kester, M.H., Bulduk, S., Tibboel, D., Meinl, W., Glatt, H., Falany, C.N., Coughtrie, M.W., Bergman, A., Safe, S.H., Kuiper, G.G., Schuur, A.G., Brouwer, A., Visser, T.J., Potent inhibition of estrogen sulfotransferase by hydroxylated PCB metabolites: a novel pathway explaining the estrogenic activity of PCBs. Endocrinology 141 (2000), 1897–1900.
55. [55] Wang, L., James, M., Sulfonation of 17β-estradiol and inhibition of sulfotransferase activity by polychlorobiphenylols and celecoxib in channel catfish, Ictalurus punctatus. Aquat. Toxicol. 81 (2007), 286–292, 10.1016/j.aquatox.2006.12.011.
56. [56] Kester, M.H., Bulduk, S., van Toor, H., Tibboel, D., Meinl, W., Glatt, H., Falany, C.N., Coughtrie, M.W., Schuur, A.G., Brouwer, A., others, Potent inhibition of estrogen sulfotransferase by hydroxylated metabolites of polyhalogenated aromatic hydrocarbons reveals alternative mechanism for estrogenic activity of endocrine disrupters. J. Clin. Endocrinol. Metab. 87 (2002), 1142–1150.
57. [57] Gosavi, R.A., Knudsen, G.A., Birnbaum, L.S., Pedersen, L.C., Mimicking of estradiol binding by flame retardants and their metabolites: a crystallographic analysis. Environ. Health Perspect. 121 (2013), 1194–1199, 10.1289/ehp.1306902.
58. [58] Prusakiewicz, J.J., Harville, H.M., Zhang, Y., Ackermann, C., Voorman, R.L., Parabens inhibit human skin estrogen sulfotransferase activity: possible link to paraben estrogenic effects. Toxicology 232 (2007), 248–256, 10.1016/j.tox.2007.01.010.